J. David Owens is a founding Partner for Bowman's Tower Venture Partners, a life science investment and company-building organization since 2016. David has been an active private investor and angel investor since 2009 and was previously a member of both the Mid-Atlantic Angel Group Fund and the Delaware Crossing Investor Group.  

Governance Experience

• OrthogenRx, Inc. – Board Director, 2013-2022
• BiologicsMD, Inc. – Board Director, 2013-2026
• ThirdLaw Molecular, Inc. – Founding Board Director, 2020-2025
• Bucks County Herald Foundation (non-profit) – Board Director, 2023-present
• Seneca Therapeutics, Inc. – Board Director, 2025-present
• Ladder Bio, Inc. – Board Observer, 2025-present
• Pennsylvania Biotechnology Center (non-profit) – Board Director, 2026-present
• Flourish Biologics, Inc. – Board Director, 2026-present

David is an experienced leader in the pharmaceutical and biotechnology industry (over 40 years) with extensive expertise in the commercialization of biopharmaceuticals and biologicals.  David’s leadership experience includes President & CEO of BiologicsMD, Inc. (New Haven, CT), Co-CEO of OrthogenRx, Inc. (sold to Avanos in 2022) and Chief Business Officer for Novira Therapeutics, Inc. (sold to J&J in 2015).  David held executive positions as Senior Vice President, and Business Unit Head of the Surgical Products Division at King Pharmaceuticals (now part of Pfizer) and prior to that as Vice President of Global Marketing & Medical Affairs at Aventis Pharma (now part of Sanofi). Earlier in his career, David held commercial operations roles at Genentech, Merck and Abbott Labs.  

David is a graduate of the University of Wisconsin, School of Pharmacy.